ClinicalTrials.gg
CompletedNCT05136677CheckMate 6DWUpdated Jan 23, 2026

A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants

A Phase 2 interventional study of Nivolumab and Ipilimumab in Mesothelioma, Malignant, sponsored by Bristol-Myers Squibb. Completed at 21 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2025, 1 year ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Mesothelioma, Malignant with a site in China — 11 open to participants now, 13 under way, 1 of them phase 3. Mesothelioma, Malignant · China.

Enrollment
6th of 18
102 · median 37
Started
2022
with 1 other
Phase 2
4 of 20
2 open now
Registered
7th of 20
by date
Lead sponsor
1 of 20
Bristol-Myers Squibb

Among the 20 studies in Mesothelioma, Malignant with a site in China, this one is the 6th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2022, is one of 4 in phase 2, and was the 7th registered.

Mesothelioma, Malignant

339 studies on the registry are indexed under Mesothelioma, Malignant; 63 are open to participants now.

Browse Mesothelioma, Malignant studies →

Open to participants now

11 of the 20 studies in Mesothelioma, Malignant with a site in China are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 54 Mesothelioma, Malignant studies recruiting now, 42 (78%) set no upper age limit and 5 (9%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Mesothelioma, Malignant with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of the combination of nivolumab and ipilimumab in Chinese participants with malignant pleural mesothelioma.

03

Conditions studied

  • Mesothelioma, Malignant

Keywords

  • Malignant Pleural Mesothelioma (MPM)
  • Nivolumab
  • Ipilimumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven diagnosis of Malignant Pleural Mesothelioma (MPM) with determination of epithelioid vs non-epithelioid histology
  • Must have advanced unresectable disease that is not amenable to therapy with curative intent (surgery with or without chemotherapy)
  • Available tumor samples for centralized testing
  • (ECOG) Performance Status of 0 to 1

Exclusion criteria

Exclusion Criteria:

  • Primitive peritoneal, pericardial, testis or tunica vaginalis mesothelioma
  • , except if surgically resected or treated with stereotaxic radiotherapy
  • Prior therapy for MPM (including chemotherapy, radical pleuropneumonectomy and non-palliative radiotherapy)

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Arm A

    Biological: Nivolumab · Biological: Ipilimumab

  • Experimental
    Arm B

    Drug: Pemetrexed · Drug: Cisplatin · Drug: Carboplatin

Interventions

  • BiologicalNivolumab

    Specified dose on specified days

    Also known as: BMS-936558, Opdivo

  • BiologicalIpilimumab

    Specified dose on specified days

    Also known as: BMS-734016, Yervoy

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Time frame: Up to 58 months

Secondary outcomes

  1. Objective Response Rate (ORR) by modified Response Evaluation Criteria in Solid Tumors (m-RECIST) by Investigator

    Time frame: Up to 58 months

  2. Progression Free Survival (PFS) by m-RECIST by Investigator

    Time frame: Up to 58 months

  3. Incidence of Adverse Events (AEs)

    Time frame: Up to 58 months

  4. Incidence of Serious Adverse Events (SAEs)

    Time frame: Up to 58 months

  5. Incidence of immune-related AEs

    Time frame: Up to 58 months

  6. Incidence of deaths

    Time frame: Up to 58 months

  7. Incidence of participants with laboratory abnormalities

    Time frame: Up to 58 months

07

Study locations

21 sites
  • Local Institution - 0009
    Beijing, Beijing Municipality 100142, China
  • Local Institution - 0013
    Harbin, Heilongjiang 150081, China
  • Local Institution - 0006
    Zhengzhou, Henan 450003, China
  • Local Institution - 0005
    Changsha, Hunan 410013, China
  • Local Institution - 0023
    Wuhan, Hunan 430023, China
  • Local Institution - 0015
    Yangzhou, Jiangsu 225001, China
  • Local Institution - 0003
    Changchun, Jilin 130021, China
  • Local Institution - 0004
    Shenyang, Liaoning 110042, China
  • Local Institution - 0021
    Shenyang, Liaoning 110044, China
  • Local Institution - 0037
    Jinan, Shandong 250117, China
  • Local Institution - 0030
    Qingdao, Shandong 266003, China
  • Local Institution - 0001
    Shanghai, Shanghai Municipality 200030, China
  • Local Institution - 0033
    Taiyuan, Shanxi 030000, China
  • Local Institution - 0029
    Chengdu, Sichuan 610041, China
  • Local Institution - 0007
    Tianjin, Tianjin Municipality 300052, China
  • Local Institution - 0018
    Tianjin, Tianjin Municipality 300060, China
  • Local Institution - 0010
    Kunming, Yunnan 650106, China
  • Local Institution - 0014
    Hangzhou, Zhejiang 310003, China
  • Local Institution - 0020
    Hangzhou, Zhejiang 310005, China
  • Local Institution - 0012
    Ningbo, Zhejiang 315010, China
  • Local Institution - 0016
    Ningbo, Zhejiang 315041, China
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Nov 2025, 45 months.

Of 48 phase 2 interventional studies under Mesothelioma, Malignant, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 87. This study's 45 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2021
First posted
Nov 29, 2021
StartActual
Jan 25, 2022
Primary completionActual
Nov 12, 2025
CompletionActual
Nov 12, 2025
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05136677
Responsible party
Sponsor
First posted
Nov 29, 2021
Start date
Jan 25, 2022
Primary completion
Nov 12, 2025
Completion
Nov 12, 2025
Last update
Jan 23, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Ipilimumab · Pemetrexed · Cisplatin · Carboplatin

Start the discussion